Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice

• Published in: Clinical and experimental rheumatology Vol. 29; no. 1; pp. 26 - 34
• Main Authors: MOOTS, R. J, HARAOUI, B, SINGH, A, MATUCCI-CERINIC, M, VAN RIEL, P. L. C. M, KEKOW, J, SCHAEVERBEKE, T, DAVIS, A, TEDESCHI, M. A, FREUNDLICH, B, CHANG, D. J
• Format: Journal Article
• Language: English
• Published: Pisa Clinical and Experimental Rheumatology 2011
• Subjects: Adalimumab; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Humanized; Antirheumatic Agents - administration & dosage; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - physiopathology; Biological and medical sciences; Bones, joints and connective tissue. Antiinflammatory agents; Diseases of the osteoarticular system; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Dosage Calculations; Etanercept; Female; Health Status; Humans; Immunoglobulin G - administration & dosage; Immunomodulators; Inflammatory joint diseases; Infliximab; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Receptors, Tumor Necrosis Factor - administration & dosage; Severity of Illness Index; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Steroid; Immunopathology; Diseases of the osteoarticular system; Antipsoriatic agent; Rheumatology; Anti-TNF; Autoimmune disease; Inflammatory joint disease; Anti-Tumor Necrosis Factor-alpha; Immunomodulator; dose escalation; Chronic; Etanercept; Infliximab; Rheumatoid arthritis; Antirheumatic agent; Immunosuppressive agent; Adalimumab; Dose; TNF-α inhibitor

To evaluate prevalence of dose escalation among RA patients in normal clinical practice treated with etanercept, adalimumab or infliximab and to estimate its economic impact. A retrospective observational study of 739 patients with RA receiving continuous treatment with etanercept (n=319), adalimuma...